Search - tctmd.com

Displaying 101 - 120 of 164

Sort: Relevancy | Date

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

News Conference News ACC 2019

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

Shelley Wood

March 11, 2019

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

Presentation Controversies and Advances 2018

Updateon PCS K-9 Inhibition

Presenter: P.K. Shah

November 15, 2018

News Daily News

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Michael O'Riordan

November 07, 2018

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

Shelley Wood

November 05, 2018

News Daily News

Vulnerable Plaque Components Seen on IVUS Not Linked With MACE, Two New Studies Show

Michael O'Riordan

October 17, 2018

News Daily News

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

Michael O'Riordan

August 02, 2018

News Daily News

Serial CTA Shines a Light on Statin Effects in Subclinical CAD

Yael L. Maxwell

June 15, 2018

News Daily News

Spin to Win: Results From Late-Breaking Meeting Trials Often Overstated

L.A. McKeown

May 15, 2018

News Daily News

Alirocumab Price Slashed in Deal With Express Scripts

Michael O'Riordan

May 03, 2018

News Conference News ACC 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Michael O'Riordan

March 20, 2018

News Conference News ACC 2018

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

Shelley Wood

March 10, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Daily News

The Biggest News of 2017: TCTMD’s Top 10

Shelley Wood

January 01, 2018

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Conference News AHA 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Michael O'Riordan

November 13, 2017

Presentation TCT 2017

Keynote Lecture: Personalized Treatment of the Vulnerable Patient With PCSK9 Inhibitors, Anti-inflammatory Therapies and CTEP Inhibitors

Presenter: Gregg W. Stone, Peter H. Stone, Evan A. Stein

November 01, 2017

News Conference News ESC 2017

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Michael O'Riordan

September 05, 2017

Advertisement

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Updateon PCS K-9 Inhibition

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

Vulnerable Plaque Components Seen on IVUS Not Linked With MACE, Two New Studies Show

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

Serial CTA Shines a Light on Statin Effects in Subclinical CAD

Spin to Win: Results From Late-Breaking Meeting Trials Often Overstated

Alirocumab Price Slashed in Deal With Express Scripts

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

The Biggest News of 2017: TCTMD’s Top 10

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Keynote Lecture: Personalized Treatment of the Vulnerable Patient With PCSK9 Inhibitors, Anti-inflammatory Therapies and CTEP Inhibitors

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content